Scribe Therapeutics Inc.
SCTX
NASDAQ21.19
USD
+0.46
- -
CIK
0001853921
ISIN
US8110331092
CUSIP
811033109
Return %
Stock
S&P500
1Y
41.27
20.11
3Y
41.27
77.01
5Y
41.27
75.93
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Benjamin L. Oakes
- Full Time Employees
- 89
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1150 MARINA VILLAGE PARKWAY Alameda CA United States of America 94501
- IPO Date
- Jul 24, 2026
- CIK
- 0001853921
- Website
- scribetx.com
- Similar Companies
- Business
- Scribe Therapeutics, Inc. develops and commercializes genome editing technologies for therapeutic applications. The company focuses on engineering CRISPR-based tools to enable precise, efficient, and safe genetic modification for in vivo and ex vivo therapies. Its core offerings include programmable nuclease systems, high-fidelity editing enzymes, delivery modalities, and associated research tools designed to advance therapeutic development. Scribe develops platform capabilities, including scalable library design, cellular screening, and validation workflows, to support product discovery and preclinical development across multiple disease areas. Core products and services include: genome editing nucleases and engineered Cas enzymes; programmable CRISPR systems and guide RNA optimization services; delivery solutions including viral and non-viral vectors and formulations; computational design and data analytics services for guide selection and off-target assessment; cellular assays and screening platforms for target validation; preclinical model development support; and collaboration-driven research programs with pharmaceutical partners. The company emphasizes end-to-end support from conceptual design through early-stage development, leveraging its proprietary editing toolbox to enable targeted genetic modifications. Geographic operations span the United States and international research partnerships, with primary headquarters in Cambridge, Massachusetts, and a focus on collaboration with biotechnology and pharmaceutical customers worldwide. Scribe operates within the life sciences industry, collaborating with academic institutions and industry partners to advance gene editing therapies. The company maintains relationships with strategic investors and industry affiliates to fund and accelerate development efforts and expand its pipeline through potential partnerships and licensing arrangements. Founding year and corporate context: Scribe Therapeutics, Inc. is established to advance programmable genome editing technologies and to translate them into therapeutic candidates, with strategic emphasis on platform optimization, safety, and delivery. The firm pursues a mission to enable durable genetic interventions by integrating engineering, biology, and translational capabilities, and maintains a subsidiary or affiliate network aligned with its core research and development objectives.
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering